☆ 4.6 Article

Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

LANCET RESPIRATORY MEDICINE (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Cell Biology

Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation

Aldo Bonaventura et al.

Summary: SARS-CoV-2 can activate NLRP3 inflammasome, leading to an inflammatory response. Colchicine, as an anti-inflammatory drug, can block the activation of NLRP3 inflammasome and reduce the release of inflammatory cytokines. Some studies have shown that colchicine may have therapeutic effects on COVID-19. However, more research is needed to confirm these findings.

INFLAMMATION RESEARCH (2022)

添加到收藏夹

Article Immunology

Randomized Study of Rivaroxaban vs Placebo on Disease Progression and Symptoms Resolution in High-Risk Adults With Mild Coronavirus Disease 2019

Jintanat Ananworanich et al.

Summary: The study found that rivaroxaban did not impact the progression of mild COVID-19 in high-risk adults. This suggests the need for scalable effective therapies to prevent COVID-19 progression in high-risk individuals.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Medicine, General & Internal

Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21

Haidong Wang et al.

Summary: This study estimated excess mortality from the COVID-19 pandemic in 191 countries and territories, as well as 252 subnational units in selected countries from Jan 1, 2020, to Dec 31, 2021. The findings showed that globally, there were 18.2 million excess deaths due to the COVID-19 pandemic during this period. The highest excess mortality rates were observed in countries such as India, the USA, Russia, Mexico, Brazil, Indonesia, and Pakistan.

LANCET (2022)

添加到收藏夹

Article Medicine, General & Internal

Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis

Ryan M. Barber et al.

Summary: Timely, accurate, and comprehensive estimation of SARS-CoV-2 infection rates are crucial for understanding past infections and transmission risks. This study provided a novel approach to estimate global and location-specific infections, combining data sources and correcting biases for more reliable estimates. The findings show staggering impacts of COVID-19 on the global population, highlighting the importance of continued research and policy responses.

LANCET (2022)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

Global vaccination must be swifter

Thomas J. Bollyky et al.

Summary: Speeding up the development of new vaccines will not be very effective in the next pandemic unless world leaders work faster to distribute vaccinations globally.

NATURE (2022)

添加到收藏夹

Article Critical Care Medicine

Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis

Jonathan R. Baker et al.

Summary: This study aimed to investigate the mechanism of action of inhaled corticosteroid budesonide in the treatment of early COVID-19. The study found that early COVID-19 disease exhibited enhanced inflammatory airway response and increased anti-viral and T-helper 1/2 (Th1/2) inflammatory response, while budesonide treatment reduced inflammation and improved T-cell response.

LANCET RESPIRATORY MEDICINE (2022)

添加到收藏夹

Article Public, Environmental & Occupational Health

Pasteur, Vaccines, and the Refusal to Become Fully Vaccinated in the Midst of the COVID-19 Pandemic

Charles S. Pavia

Summary: Vaccines are effective public health measures to prevent serious illness, but the anti-vaccine sentiment threatens vaccine acceptance by spreading false information. This essay explores the reasons behind this sentiment and proposes interventions to improve vaccine acceptance.

FRONTIERS IN PUBLIC HEALTH (2022)

添加到收藏夹

Article Hematology

Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial

Frank Cools et al.

Summary: The study results suggest that prophylaxis with low-molecular-weight heparin had no benefit for at-risk outpatients with COVID-19.

LANCET HAEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Barco et al.

Summary: This study aimed to investigate whether thromboprophylaxis with enoxaparin would prevent hospitalization and death in symptomatic COVID-19 outpatients. The results showed that enoxaparin did not reduce the risk of hospitalization and death among these patients.

LANCET HAEMATOLOGY (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges

John Eikelboom et al.

Summary: Effective treatments for COVID-19 are urgently needed, and the ACT trials aim to evaluate the efficacy of colchicine and aspirin for different severity levels of COVID-19. Despite challenges faced during the enrollment process, the results of these trials will provide important insights for future trial planning and treatment strategies.

CJC OPEN (2022)

添加到收藏夹

Article Medicine, General & Internal

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19 The ACTIV-4B Randomized Clinical Trial

Jean M. Connors et al.

Summary: This study aimed to assess the impact of anticoagulant or antiplatelet therapy on symptomatic clinically stable outpatients with COVID-19. The results showed that treatment with aspirin or apixaban compared with placebo did not reduce the rate of a composite clinical outcome, and the study was terminated early due to a lower than anticipated event rate.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19 A Randomized Clinical Trial

Rafael Diaz et al.

Summary: The study concludes that colchicine did not significantly reduce the need for mechanical ventilation or 28-day mortality in hospitalized patients with COVID-19 pneumonia.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Review Critical Care Medicine

The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

Marcin F. Osuchowski et al.

Summary: The zoonotic SARS-CoV-2 virus causing COVID-19 has devastating consequences worldwide, affecting primarily the respiratory system but also leading to long-term complications. Understanding the pathophysiology and immune response of COVID-19 is crucial for optimizing patient care and treatment strategies.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Hematology

COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year

Jenneke Leentjens et al.

Summary: There is a high incidence of venous thromboembolism in COVID-19 patients, with treatment strategies varying based on patient severity and treatment stage. High-quality evidence on antithrombotic therapy in COVID-19 patients is emerging, with ongoing studies expected to provide further guidance for clinicians.

LANCET HAEMATOLOGY (2021)

添加到收藏夹

Article Critical Care Medicine

Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial

Jean-Claude Tardif et al.

Summary: The study aimed to investigate the effect of colchicine on the composite of COVID-19-related death or hospital admission. Among patients with PCR-confirmed COVID-19, colchicine led to a lower rate of the composite of death or hospital admission than placebo.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Critical Care Medicine

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Group Author Only

Summary: The study aimed to evaluate the efficacy and safety of colchicine in treating COVID-19 patients, but found that it did not reduce 28-day mortality, hospital stay duration, or risk of progressing to invasive mechanical ventilation or death.

LANCET RESPIRATORY MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 The GRECCO-19 Randomized Clinical Trial

Spyridon G. Deftereos et al.

JAMA NETWORK OPEN (2020)

添加到收藏夹

Article Anesthesiology

Perioperative Aspirin for Prevention of Venous Thromboembolism The PeriOperative ISchemia Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials

John W. Eikelboom et al.

ANESTHESIOLOGY (2016)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Aspirin for the Prevention of Recurrent Venous Thromboembolism The INSPIRE Collaboration

John Simes et al.

CIRCULATION (2014)

添加到收藏夹

Article Medicine, Research & Experimental

Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs

Janice Pogue et al.

CLINICAL TRIALS (2009)

添加到收藏夹

Article Medicine, General & Internal

Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

LANCET (2009)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.